Stock Track | Novo Nordisk Soars 6.63% in Pre-Market as Hims & Hers Halts Competitive Weight-Loss Pill

Stock Track

Feb 09

Novo Nordisk A/S (NVO) shares surged 6.63% in pre-market trading on Monday, following news that telehealth company Hims & Hers has abandoned its plan to launch a low-cost competitor to the Danish drugmaker's blockbuster weight-loss medication.

The sharp gain comes after Hims & Hers reversed its decision over the weekend to offer a $49 compounded version of Novo Nordisk's Wegovy pill. The reversal followed legal threats from Novo Nordisk and a warning from the U.S. Food and Drug Administration (FDA), which indicated it would take action against the product for potentially violating drug regulations.

The FDA's stance against unauthorized compounded versions of GLP-1 medications, which include the key ingredient semaglutide found in Wegovy and Ozempic, strengthens Novo Nordisk's market position by removing a significant near-term competitive threat and protecting its pricing power in the lucrative weight-loss drug market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1184180865"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184180865\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184180865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184180865","market":"nz","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Soars 6.63% in Pre-Market as Hims & Hers Halts Competitive Weight-Loss Pill","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) shares surged 6.63% in pre-market trading on Monday, following news that telehealth company Hims & Hers has abandoned its plan to launch a low-cost competitor to the Danish drugmaker's blockbuster weight-loss medication.</p><p>The sharp gain comes after Hims & Hers reversed its decision over the weekend to offer a $49 compounded version of Novo Nordisk's Wegovy pill. The reversal followed legal threats from Novo Nordisk and a warning from the U.S. Food and Drug Administration (FDA), which indicated it would take action against the product for potentially violating drug regulations.</p><p>The FDA's stance against unauthorized compounded versions of GLP-1 medications, which include the key ingredient semaglutide found in Wegovy and Ozempic, strengthens Novo Nordisk's market position by removing a significant near-term competitive threat and protecting its pricing power in the lucrative weight-loss drug market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Soars 6.63% in Pre-Market as Hims & Hers Halts Competitive Weight-Loss Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Soars 6.63% in Pre-Market as Hims & Hers Halts Competitive Weight-Loss Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-09 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) shares surged 6.63% in pre-market trading on Monday, following news that telehealth company Hims & Hers has abandoned its plan to launch a low-cost competitor to the Danish drugmaker's blockbuster weight-loss medication.</p><p>The sharp gain comes after Hims & Hers reversed its decision over the weekend to offer a $49 compounded version of Novo Nordisk's Wegovy pill. The reversal followed legal threats from Novo Nordisk and a warning from the U.S. Food and Drug Administration (FDA), which indicated it would take action against the product for potentially violating drug regulations.</p><p>The FDA's stance against unauthorized compounded versions of GLP-1 medications, which include the key ingredient semaglutide found in Wegovy and Ozempic, strengthens Novo Nordisk's market position by removing a significant near-term competitive threat and protecting its pricing power in the lucrative weight-loss drug market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1184180865","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184180865","pubTimestamp":1770628000,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S (NVO) shares surged 6.63% in pre-market trading on Monday, following news that telehealth company Hims & Hers has abandoned its plan to launch a low-cost competitor to the Danish...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"个股追踪|Hims&Hers叫停竞争性减肥药诺和诺德盘前大涨6.63%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) shares surged 6.63% in pre-market trading on Monday, following news that telehealth company Hims & Hers has abandoned its plan to launch a low-cost competitor to the Danish drugmaker's blockbuster weight-loss medication.The sharp gain comes after Hims & Hers reversed its decision over the weekend to offer a $49 compounded version of Novo Nordisk's Wegovy pill. The reversal followed legal threats from Novo Nordisk and a warning from the U.S. Food and Drug Administration (FDA), which indicated it would take action against the product for potentially violating drug regulations.The FDA's stance against unauthorized compounded versions of GLP-1 medications, which include the key ingredient semaglutide found in Wegovy and Ozempic, strengthens Novo Nordisk's market position by removing a significant near-term competitive threat and protecting its pricing power in the lucrative weight-loss drug market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}